Ser21

Site Information
QVNsSLtsPTGRGsM SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 453093

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ) , mutation of modification site ( 1 )
Disease tissue studied:	breast cancer ( 5 ) , lung cancer ( 5 , 6 , 7 , 9 , 10 ) , non-small cell lung cancer ( 5 , 6 , 7 , 9 , 10 ) , non-small cell lung adenocarcinoma ( 7 ) , neuroblastoma ( 4 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) [CD38 (human), transfection, Lentiviral particles containing CD38 vector were transfected] ( 2 ) , A549 (pulmonary) ( 2 ) , Calu 6 (pulmonary) ( 5 ) , H2009 (pulmonary) ( 5 ) , H2887 (pulmonary) ( 5 ) , HCC1937 (breast cell) ( 5 ) , HeLa (cervical) ( 3 , 8 ) , hepatocyte-liver ( 1 ) , lung ( 9 , 10 ) , MCF-7 (breast cell) ( 5 ) , NB10 (neural crest) ( 4 ) , NCI-H1437 (pulmonary) ( 6 ) , NCI-H1648 (pulmonary) ( 5 ) , NCI-H1666 (pulmonary) ( 7 ) , NCI-H520 (squamous) ( 5 ) , NPC (neural crest) ( 4 ) , PC9 (pulmonary) ( 5 )

References
1	Vernia S, et al. (2022) Phosphorylation of RXRα mediates the effect of JNK to suppress hepatic FGF21 expression and promote metabolic syndrome. Proc Natl Acad Sci U S A 119, e2210434119 36282921 Curated Info
2	Wang W, et al. (2018) Decreased NAD Activates STAT3 and Integrin Pathways to Drive Epithelial-Mesenchymal Transition. Mol Cell Proteomics 29980616 Curated Info
3	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
4	DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513 24349301 Curated Info
5	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
6	Rikova K (2011) CST Curation Set: 10899; Year: 2011; Biosample/Treatment: cell line, NCI-H1437/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
7	Rikova K (2011) CST Curation Set: 10901; Year: 2011; Biosample/Treatment: cell line, NCI-H1666/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
8	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
9	Rikova K (2010) CST Curation Set: 9771; Year: 2010; Biosample/Treatment: tissue, /untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
10	Rikova K (2010) CST Curation Set: 9758; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info